MPL REMARKABLE RESULTS AGAINST COVID-19 SUPPRESSING INFECTIVITY BY 95% | Recent preliminary data from the Walter & Eliza Hall Institute has shown MPL demonstrates suppression of the COVID-19 virus’ infectivity by up to ~95%.

SUCCESSFUL PHASE II CANINE TRIALS TO ACTIVATE ELANCO LICENSING OPTION | 100% survival of patients with 6/7 dogs showing halted cancer progression & 1 dog reporting a 60% decrease in cancer. Results are to be reported to Elanco July, 2020.

HUMAN SOLID TUMOR TREATMENT MARKET IN THE 100’S OF BILLIONS | Solid tumor treatment market US$121billion in 2018, projected at US$424billion by 2027.

NON-TOXIC ALTERNATIVE TO CHEMOTHERAPY | Unlike Chemotherapy which attacks both the cancer and also normal cells, MPL is exceptionally non-toxic to normal cells and a potential replacement therapy to chemotherapy a ~$47billion per year human chemotherapy market.

INVESTMENT HIGHLIGHTS

MPL REMARKABLE RESULTS AGAINST COVID-19 SUPPRESSING INFECTIVITY BY 95% | Recent preliminary data from the Walter & Eliza Hall Institute has shown MPL demonstrates suppression of the COVID-19 virus’ infectivity by up to ~95%.

SUCCESSFUL PHASE II CANINE TRIALS TO ACTIVATE ELANCO LICENSING OPTION | 100% survival of patients with 6/7 dogs showing halted cancer progression & 1 dog reporting a 60% decrease in cancer. Results are to be reported to Elanco July, 2020.

HUMAN SOLID TUMOR TREATMENT MARKET IN THE 100’S OF BILLIONS | Solid tumor treatment market US$121billion in 2018, projected at US$424billion by 2027.

NON-TOXIC ALTERNATIVE TO CHEMOTHERAPY | Unlike Chemotherapy which attacks both the cancer and also normal cells, MPL is exceptionally non-toxic to normal cells and a potential replacement therapy to chemotherapy a ~$47billion pa market.

FUNDED BY PROFITABLE SUBSIDIARY EPICHEM | Epichem is a profitable, world class medical chemistry company, contributing to PharmAust and the WA community.

CONTINUED COMMERCIAL SUCCESS OF REPURPOSED DRUGS | Drug repurposing is a faster and less capital intensive commercial alternative to new drug development.

EXTENSIVE SUITE OF INTERNATIONAL PATENTS | PharmAust have an impressive suite of patents over the use of MPL and its analogues as an anti-cancer product.

SUCCESSFUL PHASE I CLINICAL TRIALS IN HUMANS | All trials of MPL to date have achieved primary clinical endpoints in both safety and reduction of tumour markers.

INTENDED FOR PROFESSIONAL/SOPHISTICATED INVESTOR USE ONLY
PharmAust’s key objective is to develop, synthesise and commercialise ethical, safe and effective pharmaceuticals through the company’s two wholly owned subsidiaries—Epichem and Pitney Pharmaceuticals. PharmAust’s core focus is evaluating MPL’s potential repurposing, for the treatment of cancers and COVID-19 through it’s drug development arm Pitney Pharmaceuticals. The company’s other wholly owned subsidiary is Epichem, which is a profitable world class medical chemistry company with ~$3.45million in annual revenues expected for FY 2020.

Provide services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries across the globe. Epichem have a projected $3.45million in revenue this FY and have historically not profit shared across subsidiaries, instead opting to expand Epichem to take on more contracts. Are evaluating PharmAust’s lead drug candidate MPL for the treatment of various forms of cancers in both animals and humans as well as recently discovering its effectiveness against the global pandemic COVID-19. Drug repurposing benefits are considerable in both time to market and costs.

COMMERCIAL SUCCESs OF REPURPOSED DRUGS

Current regulatory stringency, time and costs involved in new drug development has resulted in existing drug repurposing becoming a far more efficient and popular alternative. From 2007-19, 30-40% of the approved drugs or biologics launched for the first time in the US were either drugs repurposed for new indications or reformulations of existing drugs.

The extensive success of repurposed drugs is highlighted in the chart below (figure 2) with multiple repurposed brands achieving billions in annual sales. Of particular note is Spravato, an S-enantiomer for the well-known anaesthetic Ketamine which the FDA approved on just a single positive placebo-controlled trial after numerous unsuccessful trials, after the FDA highlighted a need for new depression drugs.

<table>
<thead>
<tr>
<th>BRAND NAME</th>
<th>ORIGINAL INDICATION</th>
<th>NEW INDICATION</th>
<th>PHARMACEUTICAL COMPANY</th>
<th>MAX ANNUAL SALES</th>
</tr>
</thead>
<tbody>
<tr>
<td>SPRAVATO</td>
<td>Anaesthetic (Ketamine)</td>
<td>Treatment Resistant Depression</td>
<td>Janssen/J&amp;J</td>
<td>Approved March 2019</td>
</tr>
<tr>
<td>REVLIMID</td>
<td>Anti-Nausea</td>
<td>Multiple Myeloma</td>
<td>Celgene</td>
<td>$9.7 Billion 2018</td>
</tr>
<tr>
<td>TECFIDERA</td>
<td>Psoriasis</td>
<td>Multiple Sclerosis</td>
<td>Biogen/IDEC</td>
<td>$4.0 Billion 2017</td>
</tr>
<tr>
<td>VIAGRA</td>
<td>Angina</td>
<td>Erectile Dysfunction</td>
<td>Pfizer</td>
<td>$2.05 Billion 2008</td>
</tr>
<tr>
<td>GEMZAR</td>
<td>Anti-Viral</td>
<td>Various Cancers</td>
<td>Eli Lilly</td>
<td>$1.72 Billion 2008</td>
</tr>
<tr>
<td>RITUXAN</td>
<td>Various Cancers</td>
<td>Rheumatoid Arthritis</td>
<td>Biogen &amp; Roche</td>
<td>$7.1 Billion 2015</td>
</tr>
<tr>
<td>EVISTA</td>
<td>Osteoporosis</td>
<td>Invasive Breast Cancer</td>
<td>Eli Lilly</td>
<td>$1.07 Billion 2011</td>
</tr>
<tr>
<td>PROSCAR</td>
<td>Hypertension</td>
<td>BPH</td>
<td>Merck</td>
<td>$741 Million 2008</td>
</tr>
<tr>
<td>THALOMID</td>
<td>Anti-Nausea</td>
<td>Leprosy/Multiple Myeloma</td>
<td>Celgene</td>
<td>$535 Million 2008</td>
</tr>
<tr>
<td>REVATIO</td>
<td>Angina/ED</td>
<td>PA Hypertension</td>
<td>Pfizer</td>
<td>$525 Million 2008</td>
</tr>
<tr>
<td>PROPECIA</td>
<td>Hypertension</td>
<td>Male Pattern Baldness</td>
<td>Merck</td>
<td>$429 Million 2008</td>
</tr>
<tr>
<td>ELMIRON</td>
<td>DVT</td>
<td>Interstitial Cystitis</td>
<td>Janssen/J&amp;J</td>
<td>$400 Million 2015</td>
</tr>
</tbody>
</table>

Figure 2: Repurposed Drugs or Biologics and Peak Sales post 2007
Current Solid Tumor Treatments—Preserving The Immune System

Chemotherapy kills cancer cells, however unfortunately it also targets normal cells by stopping any growth whatsoever. As such, it is considered a highly toxic treatment that harms the body’s immune system which has significant side-effects. The mTOR inhibitors Afinitor and Rapamune (Rapalogues) are also considered immunosuppressants, meaning the body cannot remain on these therapies for extended periods of time without the immune system substantially suffering.

Monepantel MPL was developed by Novartis Animal Health (Now owned by Elanco), under the name Zolvix as an anti-parasitic in the livestock industry. It inhibits the mTOR pathway, a known driver of cancer growth, effectively acting to suffocate cancer whilst preserving the body’s healthy cells. Extensive clinical data from Elanco show MPL to be safe and extremely non-toxic, allowing the ability to increase dosage significantly to target cancer, without major side-effects.

Progression Free Cancer Survival

PharmAust initially identified MPL as a frontline therapy for cancer, then proceeded to explore it in conjunction with chemotherapy. Successful results from clinical trials and low toxicity have shown MPL therapy to be a viable stand-alone endpoint therapy, where patients can live with the stable disease in solid tumors, progression free as an alternative to Chemotherapy (~$47 billion pa industry) and its harmful side effects.

Cancer In Dogs

Dogs typically suffer from majority of the same cancers as humans with very similar gene systems. The Company’s dual development strategy for MPL’s use in animals and humans is quite strategic in that the company wish to translate cancer treatment from pet dogs to humans (normally done in reverse). This results in significantly lower requirements for preclinical or pilot human safety trials, in addition to the already reduced costs and time of taking a repurposed drug through the development process as opposed to developing a new drug.

“Remarkable” Preliminary Data

The SARS-CoV-2 (COVID-19) virus was first identified in December 2019 in Wuhan, China and has since spread globally, resulting in an ongoing pandemic that to date has infected +10 million people. In April 2020 PharmAust and the Walter and Eliza Hall institute of Medical Research in Melbourne, Victoria highlighted Monepantel’s mechanism of action as inhibitor against cancer growth could be highly beneficial in the treatment of COVID-19. Repeated cell culture experiments has confirmed the promising data of MPL against COVID-19, showing both MPL and monepantel sulfone (MPLS) treatment suppressed COVID-19 cell-to-cell infectivity by ~95%. Joint head of Infectious Diseases and Immune Defence division Marc Pellegrini stated that “demonstrating twice, that infectivity of COVID-19 virus particles can be suppressed by up to ~95% in cell cultures is a remarkable outcome.”

WEHI, will now conduct a comparative analysis of MPL and other mTOR inhibitors, such as rapamycin and current anti-viral drugs authorised by the FDA for emergency use to treat COVID-19, such as remdesivir. PharmAust are also preparing an Executive Summary and an Investigator’s Brochure to advance Phase I trials for COVID-19 in a small number of human patients. As MPL has already been evaluated in human patients with cancer, the human safety data available will help to accelerate the drugs development.

Funding And Market Potential

Unfortunately the global pandemic is only beginning, FDA approved drug remdesivir has hence been projected to make A$11.3 billion in annual sales for owner Gilead Sciences by 2022. On June 2, the Morrison Government announced an additional A$66 million investment into find a vaccine and treatments for COVID-19 bringing the total of funding available to A$96 million. A$3 million has already been invested in WEHI programs that include the current and future experiments with MPL.
MONEPANTEL — ADDRESSABLE CANCER MARKET

Monepantel Therapy Recurring Revenue

MPL acts as a cancer suppressor with the potential to be taken for long periods of time at high doses to stop cancer progression. This is owing to its high safety and non-toxicity, essentially creating a therapeutic drug unlike any currently available, which can potentially be taken continuously, resulting in recurring sales to the licensee. If commercialised it is likely this drug would be priced at a premium, in line with other cancer therapies.

Companion Pet Health Market

1-in-4 dogs die of cancer, with an ageing Australian population and an increasing middle class, our companion pets are likely to be the driving veterinary expenditure increases. A 2018 report by Market Research Future predicted the companion animal segment of the animal health market is growing continuously and is expected to grow at a 9.6% CAGR during 2017–2023, reaching US$20 billion in 2023.

Improved surgical, therapeutic, and medical capabilities for companion animals will likely lead to increased life-expectancy in pets accordingly. Dogs are among the most popular pets, followed by cats. In 2017 there were a total of 60.2 million pets in US households alone.

ELANCO PARTNERSHIP — GLOBAL LICENCING OPTION

Elanco Option Agreement

In April 2018, PharmAust signed an option agreement with Elanco to develop MPL in dog cancers. Under the terms of the agreement, Elanco have supplied the Good Manufacturing Process GMP grade MPL, for use in the recent dog cancer trials. PharmAust has granted Elanco an option (“the Elanco Option”) to negotiate for an exclusive, worldwide royalty bearing commercial licence to use PharmAust’s intellectual property in the field of treatment of cancer in animals. PharmAust have managed the successful clinical trials of monepantel in dogs diagnosed Lymphoma B cancer.

Licensing Deal

Phase II results are set to be sent to Elanco, with an exercise of the option resulting in a negotiation period no longer than six months to agree to the terms of the license agreement, including commercial payments to PharmAust. A licensing deal typically involves an upfront cash payment, plus remuneration of costs spent on developing drug which is ~$15-$20m, as well as a 10-12% royalty on sales of the drug and additional milestone payments. Such a deal would mark a significant commercial outcome for PharmAust and see them fully funded for all foreseeable future activities.

The “Blue Sky” Human Market

A commercial outcome for veterinary applications would allow PharmAust to refocus on development for the much larger human market.

Should Elanco not proceed to exercise the option PharmAust will be free to seek alternative commercialisation partners.

Resulting Supply Scale-up

The agreement provides a twofold benefit to PharmAust in securing a stable supply of GMP-grade MPL that provides a scale-up opportunity ahead of dog cancer trials as well as build the relationship with a potential commercial partner.

The extensive 2019 clinical trials through the option agreement terms saw 2,000 tablets delivered in February for Phase I trials and ~15,000 tablets arriving ahead of pivotal phase II clinical trial, progressing to the commercialisation of the drug. These tablets are of GMP protocol, showing high repeatability and +12 month shelf life.

Pet Drug Market

The pet drug market was estimated at ~$10.2billion in 2018, with the willingness of owners to pay for treatment increasing to a threshold of $5,500 per companion pet. The US market is experiencing these effects and the animal health industry has witnessed considerably high-value mergers and acquisitions between major industry players. Including PharmAust option partner Elanco’s $7.6 billion merger with Bayer.

Human Oncology Market

If PharmAust’s MPL repurposing is to capture even a small market share of the existing cancer therapy market, it is in for a significant re-rating in valuation.

MPL is currently aiming to be a superior alternative to chemotherapy treatment in cancer which stand alone is a ~$47billion per annum industry.

Solid Tumor Market

The broader solid tumour applications of MPL as a cancer therapy drug could see PharmAust carve out a slice of the global treatment market, valued at US$121.3billion in 2018. Expected to reach US$424.6billion by 2027, expanding at a CAGR of 15.0% from 2019 to 2027.
PharmAust has a dual clinical development strategy for veterinary and human cancers as developing new cancer treatments from pet dogs to humans offers 3 strategic benefits. It is highly predictive, lowers risk of failure, and provides high-quality preclinical data. Many studies validate the use of dog models in studying cancer biology. Studies have shown that cancers in dogs show the same interplay of genetics, age, and environmental exposures as in humans, and that these similarities. Additionally brain cancer cells in mice that were resistant to temozolamide were reduced by MPL in preclinical trials, indicating its potential to be used in patients resistant to chemotherapy.

Early Phase Clinical Trials

Early phase trials indicated MPL’s superiority in toxicity compared with most competitors mTOR inhibitor treatments including Pfizer and Novartis already marketed drugs.

Successful Phase II Canine Clinical Trial

The recently completed Monepantel phase II canine tablet trial delivered successful anti-cancer outcomes with 100% survival of all patients and 6/7 dogs showing stable non-progression of the trial target cancer lesions. This is a viable end point in cancer treatment with a meaningful trend, allowing these dogs to continue living with the cancers on MPL. Unexpectedly 1 of the dogs also showed the complete disappearance of one cancer lesion and a 60% total decrease in cancer burden during just 14 days of monepantel tablet treatment. These results clearly display the efficacy of monepantel as an anticancer drug. Results will be presented to Elanco US Inc and provide Elanco with the opportunity to activate their 6-month exclusive option over the licensing of MPL.

‘First In Man’ Trial

MPL showed preclinical activity in ovarian, pancreatic and colorectal cancers as a monotherapy (stand-alone therapy) in mice xenografts. Based on these preclinical results, the company evaluated the anti-cancer activity of MPL in a Phase I ‘first in man’ trial.

This was a Phase I dose evaluation study, carried out at Royal Adelaide Hospital (RAH) in patients with solid tumours.

“6 from 6 of the human participants displayed reduction in p70S6k marker (mTOR pathway) and 4 of 5 patients showing a reduction in p-4E-BP1, whilst reporting better safety profiles than other anti-cancer drugs.”

Early Phase 1 Human Clinical Trial—Royal Adelaide Hospital

Extensive Suite of MPL/mTOR Patents

PharmAust has maintained an active program of patenting MPL for cancer, as well as for other diseases and disorders reliant on mTOR pathway and also for MPL analogues for which the potency may be greater or more selective. Protection of the companies intellectual property IP is vital, with MPL coming off patent in 2024. A broad range of patent protection surrounding MPL provides a growth opportunity for PharmAust into future non-cancer indications.

Based upon recent exciting findings of MPL’s suppression of COVID-19 infectivity, PharmAust have moved to broaden its Intellectual Property in the area of anti-viral activity through filing a patent application specifically covering MPL in the treatment of COVID-19.

Market Competitors

PharmAust has taken necessary precautions and registered patent protections available. Therefore, should a larger competitor want to enter this market using MPL or its analogues, they would need to enter into a deal with PharmAust.

Supply Chain

The MPL compound is owned by Elanco, with composition-of-matter patent protection out to 2024. Elanco has a first right of refusal option to use of the compound for the treatment of canine cancers. If Elanco does not take up the option, then PharmAust would require a license from Elanco to commercialise the drug independently or through another partner. However a strong relationship through the option agreement and regular collaboration should abate the potential risk.
Epichem is a wholly owned subsidiary of PharmAust Limited, they provide services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries. The Company is ISO accredited from NATA (The National Association of Testing Authorities, Australia), an internationally recognised standard of expertise which is matched by their new state-of-the-art equipped Bentley laboratory which has provided services to 35 countries worldwide for over 16 years.

Epichem Highlights Include:

- A profitable business with $3.34 million in revenues projected for FY ’19/20.
- 7 New Distribution partners recently appointed across the US, EU and Aus.
- Collaboration with not-for-profit Drugs for Neglected Disease initiative (DNDi) as part of a consortium to find a cure for Chagas Disease.
- New facility developed due to over demand for services and contract restrictions at previous facility.
- Recent expansion of its laboratory space by 50% in May 2018 in order to accommodate expanding partnerships.
- Epichem export to 33 countries worldwide with potential to become one of a select group of providers globally.
- Significant R&D tax incentive refunds with $700k refunded January 2020.

An increasing inclination of major pharma companies toward outsourcing activities related to clinical trials and increasing R&D expenditure is expected to boost demand for Epichem’s services. This presents a unique opportunity for Epichem to become a controlling supplier of chemistry services in the Australasia region and one of only a few controlling accredited suppliers globally.

KEY MANAGEMENT

Dr Roger Aston
Executive Chairman
- Dr Aston has extensive experience on boards and as CEO & Chairman of many private and publically listed biotechnology companies
- He has +30 years experience in the pharmaceutical and healthcare industries

Robert Bishop
Executive Director
- Mr Bishop has +30 years experience in corporate finance and equity capital markets.
- Experience as a Lawyer and an investment banker.

Sam Wright
Director and Co-Sec
- Mr Wright has +20 years experience in biotech and healthcare.
- Extensive experience in public company responsibilities, including ASX and ASIC compliance, corporate governance, statutory financial reporting.

Neville Bassett
Non-Executive Director
- Mr Bassett is a CA with a Member of the Order of Australia (AM).
- 35 years working in accounting, finance and stockbroking.

Dr Richard Mollard
Chief Scientific Officer
- Dr Mollard has +20 years experience in biotech and pharmaceuticals.
- Extensive national and international experience.

Colin La Galia
CEO of Epichem
- Mr La Galia has +25 years of pharmaceuticals/healthcare senior executive experience.
- Colin has also held senior leadership roles with several healthcare majors.

UPCOMING CATALYSTS

- TRIAL RESULTS AND COMMERCIALISATION PAPER SUBMIT TO ELANCO
- MONEPANTEL COVID-19 PRELIMINARY DATA SUMMARY DUE SHORTLY
- ELANCO 6-MONTH OPTION AGREEMENT ON GLOBAL LICENSING
- FURTHER ADVANCED CLINICAL TRIALS FOR MPL IN HUMANS
- PIPELINE OF FUTURE DRUG DEVELOPMENT FOR NON ONCOLOGY APPLICATIONS WITH MPL-LIKE MOLECULES
KEY RISKS

Competing products: There are several solid state tumor drugs currently in use and in development, providing a potentially crowded market. That considered through successful phase II/III trials MPL should be the top available treatment.

Clinical Trial Risk: There is a possibility that late-stage trials (Phase II/III) are unable to show the required efficacy profile or report an intolerable safety concern with MPL. Phase II trials are considered the highest risk phase of drug development.

Manufacturing Risk: Given Elanco are the rightful owners of the compound Monepantel, there is a licencing risk should Elanco not take up the global licensing rights for MPL.

IP Risk: Failure to obtain new patents or protect issued patents may negatively impact the PharmAust share price.

Funding Risks: A delay in achieving a partnership and subsequent upfront/milestone payments may have an impact on PharmAust’s clinical program development.

Timing risks: Delays in timelines may inhibit optimal partnerships, milestone payments and long-term revenues. Delays can be caused by but not limited to; trial requirements & recruitment rates; the FDA approval process; Other products reaching market.

Regulatory compliance issues: Anything from accounting issues, manufacturing practices and product recalls could materially impact our current earnings forecasts.

Poor Design of Clinical Studies: It is imperative that the correct personnel are in place to optimally design all clinical trials. As many biotech companies have experienced, an incorrectly designed study will inevitably lead to detrimental results.

SOURCES

1. Pharmast.com—Investor Centre
2. PharmAust Limited ASX Announcement—Phase I Canine Repeat Dose MPL Demonstration, 6th of May 2019
3. PharmAust Limited ASX Announcement—Agreement with University of Melbourne U-Vet for Phase II Dog Trial, 10th of September 2019
4. PharmAust Limited ASX Announcement— Confirmation of Preliminary COVID-19 Results, 18th of June 2020
5. NDF Research Report on PharmAust, 5 November 2018
7. PharmAust Limited ASX Announcement—PharmAust Signs Agreement for US Phase I, 7th of February 2019
8. PharmAust Limited ASX Announcement—PharmAust Appendix 4C and Shareholders’, 30th of April 2020
10. PharmAust Limited ASX Announcement—Optimisation of Monepantel Uptake, 21st of January 2019
11. PharmAust Limited ASX Announcement—Monepantel Principal Metabolite Shows Anti-Cancer Activity, 14th of January 2019
13. PharmAust Limited ASX Announcement—Epichem gains prestigious international ISO accreditation, 2nd of July 2018
14. PharmAust Limited ASX Announcement—PharmAust enters option to license agreement with Elanco, 18th of April 2018
16. PharmAust Limited ASX Announcement—Phase II Dog Lymphoma Trial Confirms MPL Clinical Benefit
19. New MPL analogues show greater anti-cancer activity, 23rd of November 2017
20. PharmAust Limited ASX Announcement—Monepantel Trial Achieves Successful Anti-Cancer Outcome, 12th of May, 2020

DISCLAIMER | This document has been prepared by the Sales, Trading and Investment Advisory department and not by a Research department. JP Equity Holdings Pty Ltd seeks to and does business with companies covered in its research reports. Thus, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this as only a single factor in making their investment decisions. The company featured in this document should be considered speculative in nature and carry a high degree of investment risk. Please consider if investments in these types of companies are appropriate for your personal circumstances.

This document accurately expresses the personal view of the Author at the time of writing. JP Equity Holdings Pty Ltd (ABN 98 626 933 364) is a Corporate Authorised Representative (CAR 001265594) of JP Equity Partners Pty Ltd (AFSL 512529), its directors, associates and employees advise that they may hold securities, may have an interest in and/or earn brokerage and other benefits or advantages, either directly or indirectly from client transactions arising from any advice mentioned in publications to clients. Directors, associates and employees of JP Equity Holdings Pty Ltd from time to time may hold shares in the security/securities mentioned in this Research document and, therefore, may benefit from any increase in the price of those securities.

This research note has been prepared for and is intended for Wholesale Investors only as defined by Section 761G of the Corporations Act, 2001. In accordance with Section 949A of the Corporations Act 2001, this document contains unsolicited general financial information only. In preparing this document JP Equity Holdings Pty Ltd did not consider the investment objectives, financial situation and particular needs (‘financial circumstances’) of any particular person and no recommendation (whether express or implied) contained in this document should be considered reliable. Accordingly, before acting on any information contained in this document, you should assess whether the information is appropriate in light of your own financial circumstances or contact your JP Equity Holdings Pty Ltd adviser.

JP Equity Holdings Pty Ltd believe that the information herein is accurate however no warranty of accuracy or reliability is given in relation to any information or information contained in this publication and no responsibility for any loss or damage whatsoever arising in any way for any representation, act or omission, whether express or implied (including responsibility to any persons by reason of negligence), is accepted by JP Equity Holdings Pty Ltd or any officer, agent or employee of JP Equity Holdings Pty Ltd.

No part of this report may be reproduced or distributed in any manner without permission of JP Equity Holdings Pty Ltd.